Intellia Therapeutics announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Company had previously announced the investor webcast would be held on on Monday, October 28, 2024. There are no changes to the planned oral presentation at the 2024 American College of Allergy, Asthma & Immunology Annual Scientific Meeting, taking place October 24 – 28 in Boston, Massachusetts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics announces initiation of HAELO Phase 3 study
- Intellia Therapeutics initiated with a Buy at JonesResearch
- Intellia Therapeutics price target lowered to $64 from $80 at Stifel
- Krystal Biotech price target raised to $220 from $204 at Stifel
- Beam Therapeutics price target raised to $69 from $66 at Stifel